Avantax Advisory Services Inc. Sells 1,529 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Avantax Advisory Services Inc. reduced its position in IQVIA Holdings Inc. (NYSE:IQV) by 15.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,483 shares of the medical research company’s stock after selling 1,529 shares during the period. Avantax Advisory Services Inc.’s holdings in IQVIA were worth $1,667,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Smith Group Asset Management LLC bought a new stake in shares of IQVIA in the 4th quarter worth about $1,616,000. Nordea Investment Management AB increased its stake in IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after buying an additional 452,029 shares during the period. Hickory Asset Management Inc. purchased a new stake in IQVIA in the 4th quarter valued at about $941,000. Fifth Third Bancorp grew its stake in IQVIA by 13.0% in the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock worth $2,590,000 after acquiring an additional 1,521 shares in the last quarter. Finally, Graphene Investments SAS increased its position in shares of IQVIA by 22.0% during the fourth quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company’s stock worth $2,948,000 after acquiring an additional 2,700 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Stock Performance

IQV opened at $184.64 on Tuesday. The firm has a 50 day moving average of $196.34 and a two-hundred day moving average of $209.96. The firm has a market capitalization of $32.55 billion, a PE ratio of 24.62, a P/E/G ratio of 1.99 and a beta of 1.50. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 12-month low of $179.28 and a 12-month high of $256.34.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. UBS Group reduced their price target on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a report on Friday, February 7th. Truist Financial reiterated a “buy” rating and issued a $263.00 price target (up from $261.00) on shares of IQVIA in a report on Monday, February 10th. Bank of America dropped their price objective on IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th. Finally, Robert W. Baird lowered their price target on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, January 21st. Five investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.